Evidence map›Paper›PMID 31621997›Full record

ArticleChembiochem : a European journal of chemical biology2020

OleD Loki as a Catalyst for Hydroxamate Glycosylation.

Ryan R Hughes, Khaled A Shaaban, Larissa V Ponomareva, Jamie Horn, Chunhui Zhang, Chang-Guo Zhan, S Randal Voss, Markos Leggas, Jon S Thorson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ryan R HughesCenter for Pharmaceutical Research and Innovation, College of Pharmacy, Department of Pharmaceutical Sciences, University of Kentucky, 789 South Limestone Street, Lexington, KY, 40536, USA.
Khaled A ShaabanCenter for Pharmaceutical Research and Innovation, College of Pharmacy, Department of Pharmaceutical Sciences, University of Kentucky, 789 South Limestone Street, Lexington, KY, 40536, USA.ORCID 0000-0001-7638-4942
Larissa V PonomarevaCenter for Pharmaceutical Research and Innovation, College of Pharmacy, Department of Pharmaceutical Sciences, University of Kentucky, 789 South Limestone Street, Lexington, KY, 40536, USA.ORCID 0000-0003-2182-8774
Jamie HornCenter for Pharmaceutical Research and Innovation, College of Pharmacy, Department of Pharmaceutical Sciences, University of Kentucky, 789 South Limestone Street, Lexington, KY, 40536, USA.
Chunhui ZhangCenter for Pharmaceutical Research and Innovation, College of Pharmacy, Department of Pharmaceutical Sciences, University of Kentucky, 789 South Limestone Street, Lexington, KY, 40536, USA.
Chang-Guo ZhanCenter for Pharmaceutical Research and Innovation, College of Pharmacy, Department of Pharmaceutical Sciences, University of Kentucky, 789 South Limestone Street, Lexington, KY, 40536, USA.
S Randal VossDepartment of Neuroscience, Spinal Cord and Brain Injury Research Center, Ambystoma Genetic Stock Center, University of Kentucky, UK Medical Center MN 150, Lexington, KY, 40536, USA.ORCID 0000-0002-8332-3176
Markos LeggasCenter for Pharmaceutical Research and Innovation, College of Pharmacy, Department of Pharmaceutical Sciences, University of Kentucky, 789 South Limestone Street, Lexington, KY, 40536, USA.
Jon S ThorsonCenter for Pharmaceutical Research and Innovation, College of Pharmacy, Department of Pharmaceutical Sciences, University of Kentucky, 789 South Limestone Street, Lexington, KY, 40536, USA.ORCID 0000-0002-7148-0721

Funding

Kentucky Center for Clinical and Translational ScienceUL1TR001998 · NCATS · UNIVERSITY OF KENTUCKY · PI HARTMANN, KATHERINE E, KERN, PHILIP A · 2016 to 2025
$34.2M
Kentucky Center for Clinical and Translational ScienceUL1TR000117 · NCATS · UNIVERSITY OF KENTUCKY · PI KERN, PHILIP A · 2012 to 2015
$13.3M
In Vitro Glycorandomization of Natural ProductsR37AI052218 · NIAID · UNIVERSITY OF KENTUCKY · PI THORSON, JON SCOTT · 2012 to 2021
$4.0M
Developing Regeneration Resources for a Model AmphibianR24OD021479 · OD · UNIVERSITY OF KENTUCKY · PI THORSON, JON SCOTT, VOSS, STEPHEN RANDAL · 2016 to 2019
$2.3M
NCATS NIH HHS UL1 TR000117NCATS NIH HHS UL1 TR001998NIAID NIH HHS R37 AI052218NIH HHS R24 OD021479
6 · The paper itself

Abstract

Herein we describe the ability of the permissive glycosyltransferase (GT) OleD Loki to convert a diverse set of >15 histone deacetylase (HDAC) inhibitors (HDACis) into their corresponding hydroxamate glycosyl esters. Representative glycosyl esters were subsequently evaluated in assays for cancer cell line cytotoxicity, chemical and enzymatic stability, and axolotl embryo tail regeneration. Computational substrate docking models were predictive of enzyme-catalyzed turnover and suggest certain HDACis may form unproductive, potentially inhibitory, complexes with GTs.

Indexed as

Bacterial ProteinsBinding SitesBiocatalysisCell Line, TumorCell SurvivalGlucosyltransferasesGlycosylationHistone Deacetylase InhibitorsHumansHydroxamic AcidsMolecular Docking SimulationSubstrate SpecificityBacterial ProteinsGlucosyltransferasesHistone Deacetylase InhibitorsHydroxamic AcidsOleD protein, Streptomyces antibioticustrichostatin AglucosylationglycosyltransferaseHDAChistone deacetylase

Identifiers

PMID31621997
PMCPMC7124993

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.